Department of Error (DOI:10.1016/S0140-6736(07)61605-5);Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

Lancet

Volumn 370, Issue 9600, 2007, Pages 1698-1705

  Chi, Benjamin H ^a,b   Sinkala, Moses ^b,c   Mbewe, Felistas ^a   Cantrell, Ronald A ^a,b   Kruse, Gina ^a   Chintu, Namwinga ^a   Aldrovandi, Grace M ^d   Stringer, Elizabeth M ^a,b   Kankasa, Chipepo ^e   Safrit, Jeffrey T ^f   Stringer, Jeffrey SA ^a,b  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Catholic Medical Mission Board   (Zambia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY TEACHING HOSPITAL   (Zambia)

^f ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAPARTUM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SINGLE DRUG DOSE; STANDARD; TREATMENT OUTCOME; VIRUS RESISTANCE; ZAMBIA;

EID: 36049039178     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60302-5     Document Type: Erratum

References (45)

1. Stringer E., Sinkala M., Stringer J., et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 17 (2003) 1377-1382
2. Ayouba A., Tene G., Cunin P., et al. Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 34 (2003) 274-280
3. Perez F., Orne-Gliemann J., Mukotekwa T., et al. Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. BMJ 329 (2004) 1147-1150
4. Welty T., Bulterys M., Welty E., et al. Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. J Acquir Immune Defic Syndr 40 (2005) 486-493
5. Temmerman M., Quaghebeur A., Mwanyumba F., and Mandaliya K. Mother-to-child HIV transmission in resource poor settings: how to improve coverage?. AIDS 17 (2003) 1239-1242
6. Van't Hoog A., Mbori-Ngacha D., Marum L., et al. Preventing mother-to-child transmission of HIV in Western Kenya: operational issues. J Acquir Immune Defic Syndr 40 (2005) 344-349
7. Eshleman S., Mracna M., Guay L., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15 (2001) 1951-1957
8. Eshleman S., Hoover D., Chen S., et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192 (2005) 30-36
9. Johnson J., Li J., Morris L., et al. Emergence of Drug-Resistant HIV-1 after Intrapartum Administration of Single-Dose Nevirapine Is Substantially Underestimated. J Infect Dis 192 (2005) 16-23
10. Jourdain G., Ngo-Giang-Huong N., Le Coeur S., et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351 (2004) 229-240
11. Shapiro R., Thior I., Gilbert P., et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 20 (2006) 1281-1288
12. Chaix M., Ekouevi D., Rouet F., et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 193 (2006) 482-487
13. Lockman S., Shapiro R., Smeaton L., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 (2007) 135-147
14. Chi B., Sinkala M., Stringer E., et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21 (2007) 957-964
15. Coovadia A, Marais B, Abrams EJ, et al. Virologic response to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier [Abstract 641]. 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO, USA, 2006.
16. Barditch-Crovo P., Deeks S., Collier A., et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 45 (2001) 2733-2739
17. Rousseau F., Wakeford C., Mommeja-Marin H., et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 188 (2003) 1652-1658
18. Chi B., Chintu N., Lee A., Stringer E., Sinkala M., and Stringer J. Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia. J Acquir Immune Defic Syndr 45 (2007) 125-127
19. Stringer J., Zulu I., Levy J., et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 (2006) 782-793
20. Stringer J., Sinkala M., Chapman V., et al. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 17 (2003) 1659-1665
21. Tobin N., Learn G., Holte S., et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79 (2005) 9625-9634
22. Stanford University. HIV Drug Resistance Database. Stanford CA, USA: Stanford University. http://hivdb.stanford.edu/ (accessed July 10, 2007).
23. Hirsch M., Conway B., D'Aquila R., et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279 (1998) 1984-1991
24. Johnson V., Brun-Vezinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14 (2006) 125-130
25. Bryson Y., Luzuriaga K., Sullivan J., and Wara D. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 327 (1992) 1246-1267
26. Stringer J., Sinkala M., Stout J., et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr 32 (2003) 506-513
27. Stringer J., Sinkala M., Maclean C., et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS 19 (2005) 1309-1315
28. Stringer J., Sinkala M., Goldenberg R., Vermund S., and Acosta E. Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1. Lancet 362 (2003) 667
29. Laurito T., Santagada V., Caliendo G., Oliveira C., Barrientos-Astigarraga R., and De Nucci G. Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J Mass Spectrom 37 (2002) 434-441
30. National Institutes of Health Division of AIDS. Table for grading the severity of adult and pediatric adverse events: December 2004. http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf (accessed on July 10, 2007).
31. Spensley AN, Wilfert CM. PMTCT services in higher prevalence countries: implications for future program direction [Abstract TUPE0338]. XVI International AIDS Conference; Toronto, Canada; 2006.
32. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access (2006), World Health Organization, Geneva, Switzerland
33. McIntyre J, Martinson N, Gray G, et al. Addition of short-course combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the development of maternal and paediatric NNRTI-resistant virus. 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janiero, Brazil, 2005.
34. Coffie P, Ekouevi D, Chaix ML, et al. Short-course zidovudine and lamivudine or single-dose nevirapine containing PMTCT compromises 12-month response to HAART in African women in Abidjan, Cote d'Ivoire (2003-2006) [Abstract 93LB]. 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, CA, USA, 2007.
35. Kiarie J., Kreiss J., Richardson B., and John-Stewart G. Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. AIDS 17 (2003) 65-71
36. Zambian Ministry of Health. Antiretroviral therapy for chronic HIV infection in adults and adolescents: new ART protocols, May 2007 (2007), Printech Press, Lusaka, Zambia
37. Eshleman S., Guay L., Mwatha A., et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 20 (2004) 595-599
38. Eshleman S., Guay L., Wang J., et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 40 (2005) 24-29
39. Lallemant M., Jourdain G., Le Coeur S., et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351 (2004) 217-228
40. Dabis F., Bequent L., Ekouevi D., et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19 (2005) 309-318
41. Loubser S., Balfe P., Sherman G., Hammer S., Kuhn L., and Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20 (2006) 995-1002
42. Flys T., Nissley D., Claasen C., et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192 (2005) 24-29
43. Chaix M., Ekouevi D., Peytavin G., et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrobl Agents Chemother 51 (2007) 896-901
44. Eshleman S., Hoover D., Chen S., et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19 (2005) 2167-2169
45. Martinson N., Morris L., Gray G., et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 44 (2007) 148-153